Hepatocellular carcinoma (HCC) is a major and increasing cause of clinical and economic burden worldwide. Now that there are effective therapies to control or eradicate viral aetiologies, the landscape of HCC is chang...Hepatocellular carcinoma (HCC) is a major and increasing cause of clinical and economic burden worldwide. Now that there are effective therapies to control or eradicate viral aetiologies, the landscape of HCC is changing with alcoholic and metabolic liver diseases becoming major catalysts. The pathogenesis of HCC is complex and incompletely understood, hampering improvements in therapy. Animal models are essential tools for advancing study on the cellular and molecular processes in HCC and for screening potential novel therapies. Many models of hepatocarcinogenesis have been established using various methods including genetic engineering, chemotoxic agents and dietary manipulation to direct implantation of tumour cells. However, none of these can accurately replicate all features found in human diseases. In this review, we provide an overview of different mouse models of HCC with a particular focus on cancer arising from alcoholic liver disease, non-alcoholic fatty liver disease and hereditary haemochromatosis. We also highlight their strengths and limitations and provide perspectives for future study.展开更多
Metabolic dysfunction-associated fatty liver disease(MAFLD)is the liver manifestation of metabolic syndrome,a rapidly growing clinical and public health issue mirrored by epidemic rates of obesity,type 2 diabetes mell...Metabolic dysfunction-associated fatty liver disease(MAFLD)is the liver manifestation of metabolic syndrome,a rapidly growing clinical and public health issue mirrored by epidemic rates of obesity,type 2 diabetes mellitus,hypertension and cardiovascular disease(CVD).Besides MAFLD,nomenclature used to capture fatty liver disease not primarily due to alcohol excess include non-alcoholic fatty liver disease(NAFLD)and metabolic dysfunction-associated steatotic liver disease(MASLD).Regardless of the terminology used,these diagnoses describe the most common cause of chronic liver disease globally.Accordingly,MAFLD is poised to become the leading cause of hepatocellular carcinoma(HCC)and end-stage liver disease requiring liver transplantation around the world(1,2).In addition to this,CVD and extra-hepatic cancers are the two main causes of death in the MAFLD population.Thus,MAFLD poses a severe clinical burden which is projected to worsen in the future and intervention is urgently needed.展开更多
文摘Hepatocellular carcinoma (HCC) is a major and increasing cause of clinical and economic burden worldwide. Now that there are effective therapies to control or eradicate viral aetiologies, the landscape of HCC is changing with alcoholic and metabolic liver diseases becoming major catalysts. The pathogenesis of HCC is complex and incompletely understood, hampering improvements in therapy. Animal models are essential tools for advancing study on the cellular and molecular processes in HCC and for screening potential novel therapies. Many models of hepatocarcinogenesis have been established using various methods including genetic engineering, chemotoxic agents and dietary manipulation to direct implantation of tumour cells. However, none of these can accurately replicate all features found in human diseases. In this review, we provide an overview of different mouse models of HCC with a particular focus on cancer arising from alcoholic liver disease, non-alcoholic fatty liver disease and hereditary haemochromatosis. We also highlight their strengths and limitations and provide perspectives for future study.
文摘Metabolic dysfunction-associated fatty liver disease(MAFLD)is the liver manifestation of metabolic syndrome,a rapidly growing clinical and public health issue mirrored by epidemic rates of obesity,type 2 diabetes mellitus,hypertension and cardiovascular disease(CVD).Besides MAFLD,nomenclature used to capture fatty liver disease not primarily due to alcohol excess include non-alcoholic fatty liver disease(NAFLD)and metabolic dysfunction-associated steatotic liver disease(MASLD).Regardless of the terminology used,these diagnoses describe the most common cause of chronic liver disease globally.Accordingly,MAFLD is poised to become the leading cause of hepatocellular carcinoma(HCC)and end-stage liver disease requiring liver transplantation around the world(1,2).In addition to this,CVD and extra-hepatic cancers are the two main causes of death in the MAFLD population.Thus,MAFLD poses a severe clinical burden which is projected to worsen in the future and intervention is urgently needed.
